hydroxymethylvinyl ketone: a metabolite of 1,3-butadiene; structure in first source
ID Source | ID |
---|---|
PubMed CID | 12369703 |
MeSH ID | M0480142 |
Synonym |
---|
52642-66-7 |
1-hydroxybut-3-en-2-one |
hydroxymethylvinyl ketone |
LHBQGXZUVXFJRH-UHFFFAOYSA-N |
DTXSID10494754 |
vinylidenglykol |
FT-0700954 |
Hydroxymethylvinyl ketone (HMVK) is a reactive oxidation product of 3-butene-1,2-diol, a metabolite of 1,3-butadiene.
Excerpt | Reference | Relevance |
---|---|---|
"Hydroxymethylvinyl ketone (HMVK) is a reactive oxidation product of 3-butene-1,2-diol, a metabolite of 1,3-butadiene. " | ( Mass spectral analyses of hemoglobin adducts formed after in vitro exposure of erythrocytes to hydroxymethylvinyl ketone. Barshteyn, N; Elfarra, AA; Krause, RJ, 2007) | 2 |
Excerpt | Relevance | Reference |
---|---|---|
" We previously demonstrated similarities in the shapes of the dose-response curves for EB-diol derived DNA adducts, hemoglobin adducts, and Hprt mutant frequencies in BD-diol exposed rodents, indicating that EB-diol was involved in the mutagenic response associated with BD-diol exposure." | ( The importance of 3,4-epoxy-1,2-butanediol and hydroxymethylvinyl ketone in 3-butene-1,2-diol associated mutagenicity. Li, Y; Powley, MW; Swenberg, JA; Upton, PB; Walker, VE, 2007) | 0.6 |
" In the present study, we used multiple mass spectrometry techniques to investigate the formation of HMVK adducts with nucleophilic residues of Hb in vivo after dosing Sprague-Dawley rats with 25 and 200 mg/kg BDD." | ( Mass spectral analyses of hydroxymethylvinyl ketone-hemoglobin adducts formed after in vivo exposure of Sprague-Dawley rats to 3-butene-1,2-diol. Barshteyn, N; Elfarra, AA, 2009) | 0.65 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (85.71) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |